Joël Guigay
Nice oncologist who led TPExtreme, the GORTEC trial that showed the shorter TPEx regimen is a reasonable alternative to EXTREME for recurrent or metastatic head and neck cancer.
Overview
Joël Guigay is a medical oncologist at Centre Antoine Lacassagne in Nice and a leader of the French GORTEC head and neck group. He was first author of the 2021 Lancet Oncology report of TPExtreme, the phase 2 trial comparing docetaxel, cisplatin and cetuximab (TPEx) with the EXTREME regimen as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma; TPEx did not lengthen survival but was less toxic and shorter, and is used as an alternative.
Similar pages
not linked directly; found by shared links- PersonJean-Pascal Machiels
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
- PersonAnthony C. Nichols
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
- PersonRobert L. Ferris
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
- PersonDanny Rischin
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
- PersonEzra E. W. Cohen
Shares Head and neck squamous cell carcinoma and the tag head-and-neck.
- TrialStudy of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
- TrialClinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
- TrialSafety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.